Moderna Therapeutics has scored another coup. The biotech, which struck a major development deal with AstraZeneca ($AZN) just months after it shed stealth status, has landed former Genzyme CEO Henri Termeer for the board of directors. Report
Moderna Therapeutics has scored another coup. The biotech, which struck a major development deal with AstraZeneca ($AZN) just months after it shed stealth status, has landed former Genzyme CEO Henri Termeer for the board of directors. Report